Even so, KRAS mutant tumors remain highly heterogeneous, and further exploration into biological subtypes and molecular targets is warranted to guide prognosis and treatment of patients with KRAS mutant CRC.48 This evidence concerns the gene KRAS and colorectal carcinoma.